Tag

NASDAQ: BIIB

Climb Bio reports 38% immunologic remission in kidney trial
Adrian Kessler · Oct 24, 2026
Immunovant drops cutaneous lupus program after IMVT‑1402 trial miss
Adrian Kessler · Sep 23, 2026